Member Info for Shukan

Ummmmmm - obviously not researched, of course its not to- morrow that’s why you can buy at above 4p

Agree

POTNAK another clown - FILTERED

look at his portfolio - on board a micro cap - not without due diligence

Dr Shepard a pioneer in modern cancer research - exciting times ahead

Nice trades - all good

Yes you will not be disappointed, as said before I have met with the company just after admission to the stock exchange, at one of the presentations ,this guy is passionate and on the ball, over sold to 2.1p and of course was adding a few more , now with warrants I hold a shade over 2.1m shares, look who are locked in at 3.5p on RTO it’s mouth watering reading for those that research, early days we have the payload now it’s time for the engine

With what I read, may be locked in for a while

I will of course it would be interesting for sure

If you research their biotech and compare it to the potential here with Hemogenyx well I’ll let you fill in the rest

28 Aug 2017 · Biotech giant Gilead Sciences is beefing up its cancer drug portfolio with a $11.9 billion deal to buy Kite Pharma, a company focused on a groundbreaking new class of treatments that turns the body's own immune cells into targeted blood cancer killers.

No I have not looked to be fair you could by the way look at the acquisition of KITE - 2017 $180 a Share

Nope

Sorry what was your question?

Left a message for you on my Twitter feed Be a MAN and reply would like a chat

You can’t let an idiot run riot though - any way good news for Domestos Dave - Been head hunted by the pharmaceutical industry as they just got wind that bleach and bonfires is the way to go for vitro.

Out the stock is MAIN MARKET small free float not AIM follow the facts not a dish full of bleach

Yes - he knows - he was looking at 2.1p unfortunately the boat has sailed , throwing tantrum here on the BB

A natural progression from Proof of Concept in huminised mice to Vitro as CDX is the proof concept and Vitro the preparation of AML and CDX in an environment that both types can flourish - we await the next move from Hemogenyx in relation to their POC . Interesting times ahead.

DD agenda here is astonishing considering Hemogenyx push to save human life, his argument in fact is a red herring, there is a normal progression from proof of principle in huminised mice to vitro, the coming weeks /months will establish this fact with news flow , for new investors and those thinking about it we have a CEO who,s passionate about his work, it is NOT a life style Company for Dr Vladislav.Since 2011 working for personalised therapy of blood cancer patients without harmful side affects as we have in 2018 has to be applauded not ridiculed by idiots like Domestos Dave.